NAD+ and BPC-157 energy claims: what the evidence says

What's this video probably claiming?

Based on the caption, @thekelseyrose_ completed what she's calling a "cycle" of NAD+ (likely IV or subcutaneous) combined with BPC-157, and she's reporting a significant increase in energy as the standout benefit. Given the peptide community's current obsession with stacking compounds, she's almost certainly also gesturing toward improved recovery, better sleep, and possibly some kind of gut or injury healing benefit from the BPC-157 side. The framing of a "first full round" implies she's treating these compounds like a structured course, with before-and-after reporting. That's a relatable format that gets traction, but it sets up a classic anecdote-as-evidence problem. She's describing personal experience with two compounds that have very different mechanisms, very different evidence bases, and no established clinical protocol for combining them in humans.

What does the science actually show?

NAD+ precursor research, mostly done with NMN and NR rather than direct NAD+ administration, shows some legitimate signal. A 2023 randomized trial by Liao et al. in Nature Aging found NMN supplementation improved muscle insulin sensitivity and physical performance in older adults at 300mg daily over 12 weeks, but the effect sizes were modest. Direct IV NAD+ has almost no peer-reviewed clinical trial data supporting energy enhancement in otherwise healthy adults. BPC-157 is where the evidence gap gets serious. Every study showing accelerating tendon repair, gut healing, and anti-inflammatory effects has been conducted in rats or rodents, typically at doses around 10 micrograms per kilogram body weight injected locally. Sebecic and Nikolić-Parac published rodent work in Journal of Physiology-Paris as far back as 1998. There is, to date, no published Phase II or Phase III human trial on BPC-157 for any indication.

Where does the social media noise diverge from clinical reality?

The biggest divergence is the word "cycle." That term imports a bodybuilding framework, implying that running these compounds for a defined period, stopping, then repeating produces predictable, optimized results. No human pharmacokinetic data exists to support cycling BPC-157 in healthy people. The energy claims tied to NAD+ also deserve scrutiny. Feeling more energetic after starting a new wellness protocol is textbook placebo territory, especially when someone is motivated enough to inject themselves and document the experience publicly. A 2020 meta-analysis by Trammell et al. in Cell Metabolism found NAD+ precursor supplementation reliably raised blood NAD+ levels, but the translation from elevated NAD+ to subjective energy in young, healthy adults is not established. Social media compresses that uncertainty into a confidence nobody has earned yet.

What should you actually know?

If you're considering either of these compounds, the regulatory context matters. BPC-157 is not FDA-approved for any human use. It exists in a compounding gray zone and has been on the FDA's radar for restrictions. NAD+ infusions are offered at many clinics but are not FDA-approved treatments for fatigue or aging. The safety profile of BPC-157 in humans is genuinely unknown because the trials haven't been done. That's not a fringe concern, that's a basic pharmacology fact. Stacking two under-studied compounds without clinical oversight adds risk that no influencer update can quantify. FormBlends works with licensed providers who can evaluate whether peptide therapy is appropriate for your specific situation, including labs and health history, not just what felt good in someone's TikTok recap. Personal experience shared online is not a substitute for that evaluation.